Key result
High baseline vaspin levels (≥2.5 ng/mL) were associated with significantly better metabolic profiles, including lower HOMA (p=0.018) and higher HDL cholesterol (p<0.0001) over 12 months post-bariatric surgery.
Why the study?
Are high baseline vaspin levels associated with better metabolic outcomes in severely obese patients undergoing bariatric surgery?
Cohort (n=77)
No
Are high baseline vaspin levels associated with better metabolic outcomes in severely obese patients undergoing bariatric surgery?
p-value: p=<0.05
Higher baseline vaspin levels in severely obese patients undergoing bariatric surgery are associated with a more favorable metabolic and lipid profile both pre- and post-operatively.
May support vaspin as a prognostic marker post-bariatric surgery; hypothesis-generating and should not yet change practice.
PURPOSE: Vaspin (visceral-adipose-tissue-derived-serine-protease-inhibitor) is a recently identified adipokine with putative insulin-sensitizing properties. Plasma vaspin responses to surgery-induced weight loss are sparse and contradictory. DESIGN AND PARTICIPANTS: We evaluated changes in vaspin levels and relationship to post-operative outcomes in men (n = 22) and women (n = 55) undergoing biliopancreatic-diversion/duodenal-switch bariatric surgery. Body composition and plasma parameters were measured at baseline, acutely (1 and 5 days) and medium-term (6 and 12 months) post-surgery. RESULTS: Fasting preoperative vaspin concentrations were comparable in men vs women. The distribution was biphasic (both men and women) with a nadir of 2.5 ng/ml. Subjects were divided into high (≥2.5 ng/mL, HI-group) and low (<2.5 ng/mL, LO-group) vaspin level. Both groups had comparable sex distribution, age and BMI, but the HI-vaspin group had lower insulin, HOMA, and triglyceride and higher HDL-cholesterol, acylation stimulating protein (ASP) and IL-6 levels (all p<0.05). Post-operatively, both groups decreased BMI comparably over 12 months; the HI-vaspin group maintained high vaspin levels, while the LO-vaspin group gradually increased their levels with weight loss over 12 months. The HI-vaspin group maintained a better glucose, insulin, HOMA, fructosamine, HDL-cholesterol, and triglyceride profile throughout. The HI-vaspin group also had higher gamma-glutamyltransferase and ASP profiles. Finally, baseline vaspin level inversely correlated significantly with baseline and 12-month insulin, HOMA, triglyceride and positively correlated with HDL and ASP. Twelve-month vaspin also correlated similarly, including an inverse correlation with BMI. CONCLUSION: Globally, this study supports the concept of vaspin as a beneficial adipokine in obesity, which may potentially lead to possible therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2014) conducted a cohort in Severe obesity (n=77). High baseline vaspin levels (≥2.5 ng/mL) vs. Low baseline vaspin levels (<2.5 ng/mL) was evaluated on Metabolic profile (HOMA, insulin, lipids) over 12 months (p=<0.05). High baseline vaspin levels (≥2.5 ng/mL) were associated with significantly better metabolic profiles, including lower HOMA (p=0.018) and higher HDL cholesterol (p<0.0001) over 12 months post-bariatric surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: